Maintenance Notice (4:00 PM July 4 - 10:00 PM July 6, 2025):
This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.198
Maximum quantity allowed is 999
Please select the quantity
Bone Resorption Inhibitor
No.165(April 2015)
Zoledronic acid (1) is a bisphosphonate (BP), which inhibits bone resorption, and is classified as a third-generation heterocyclic nitrogen-containing BP.1,2) The third-generation BPs inhibit farnesyl pyrophosphate synthetase.2) As well as other BPs, 1 binds to the calcium phosphate bone mineral hydroxyapatite with high affinity and, when compared with other BPs in vitro, 1 has the highest affinity for hydroxyapatite (1 > alendronate > ibandronate > risedronate > etidronate > clodronate).3) 1 has been used in the treatment of osteoporosis,4) Paget’s disease,5) and hypercalcemia of malignancy.6)
References
- 1)Bisphosphonates: From bench to bedside
- 2)Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase
- 3)Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite
- 4)Role of zoledronic acid in the prevention and treatment of osteoporosis
- 5)Emerging strategies and therapies for treatment of Paget’s disease of bone
- 6)The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy
The prices are subject to change without notice. Please confirm the newest price by our online catalog before placing an order.
In addition, sales products changes with areas. Please understand that a product is not available when the product details page is not displayed.
In addition, sales products changes with areas. Please understand that a product is not available when the product details page is not displayed.